Diabetes
Conditions
Interventions
Participants were treated with insulin glargine for two days. Insulin glargine was replaced to insulin degludec with same insulin dosage on the third day. CGM was recorded from the start of the study
Sponsors
Diabetes Therapeutics and Research Center, The University of Tokushima
Terasawa Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients with diabetes, who are on insulin glargine treatment, whose glargine dose was titrated to adjust bedtime and prebreakfast blood glucose equally (<30mg/dl).
Exclusion criteria
Exclusion criteria: 1. Patients who cannot record their blood glucose results. 2. Patients who cannot come to the clinic regularly. 3. Patients who are not allowed to keep good blood glucose management. 4. Patients who are considered tobe inappropriate for this trial by the physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hypoglycemia frequency and insulin degludec requirement during 2 months after switching from insulin glargine. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body weight change, clinical parameters, and other side effects 2 months after switching from insulin glargine. | — |
Countries
Japan
Contacts
Public ContactAkio Kuroda
The University of Tokushima Diabetes Therapeutics and Research Center
Outcome results
None listed